 Alessandra Maleddu
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Stromal Tumors | 10 | 2011 | 43 | 1.320 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 2023 | 7 | 0.860 |
Why?
| | Antineoplastic Agents | 6 | 2023 | 1879 | 0.780 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 6 | 2011 | 40 | 0.610 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2011 | 63 | 0.580 |
Why?
| | Positron-Emission Tomography | 7 | 2011 | 259 | 0.560 |
Why?
| | Liver Neoplasms | 3 | 2009 | 506 | 0.320 |
Why?
| | Pyrroles | 1 | 2009 | 181 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 3 | 2009 | 785 | 0.290 |
Why?
| | Carcinoma, Renal Cell | 1 | 2009 | 168 | 0.280 |
Why?
| | Indoles | 1 | 2009 | 304 | 0.280 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2009 | 395 | 0.260 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 327 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 636 | 0.240 |
Why?
| | Colorectal Neoplasms | 4 | 2011 | 615 | 0.210 |
Why?
| | Quinazolines | 1 | 2023 | 240 | 0.190 |
Why?
| | Osteosarcoma | 1 | 2021 | 67 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 64 | 0.180 |
Why?
| | Gene Expression Profiling | 4 | 2011 | 1518 | 0.180 |
Why?
| | Sarcoma | 1 | 2021 | 137 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2021 | 194 | 0.170 |
Why?
| | Radiopharmaceuticals | 2 | 2008 | 157 | 0.140 |
Why?
| | Biomarkers, Tumor | 3 | 2011 | 1040 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2011 | 554 | 0.140 |
Why?
| | DNA Mutational Analysis | 3 | 2011 | 372 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2011 | 1141 | 0.120 |
Why?
| | Neoplasms | 4 | 2009 | 2097 | 0.120 |
Why?
| | Carbon Radioisotopes | 2 | 2009 | 36 | 0.100 |
Why?
| | Interstitial Cells of Cajal | 1 | 2011 | 4 | 0.100 |
Why?
| | Stem Cell Factor | 1 | 2011 | 14 | 0.100 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 25 | 0.100 |
Why?
| | Stomach Neoplasms | 2 | 2009 | 65 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2009 | 113 | 0.100 |
Why?
| | Humans | 21 | 2023 | 114616 | 0.100 |
Why?
| | Mutation | 3 | 2010 | 3344 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 740 | 0.090 |
Why?
| | Medical Oncology | 2 | 2008 | 229 | 0.090 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 58 | 0.080 |
Why?
| | Gene Amplification | 1 | 2009 | 95 | 0.080 |
Why?
| | Adrenalectomy | 1 | 2009 | 60 | 0.080 |
Why?
| | Diagnostic Imaging | 2 | 2008 | 275 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2011 | 2552 | 0.080 |
Why?
| | Nuclear Medicine | 1 | 2008 | 7 | 0.080 |
Why?
| | Molecular Probes | 1 | 2008 | 30 | 0.080 |
Why?
| | Esophagitis | 1 | 2009 | 65 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 81 | 0.080 |
Why?
| | Antibodies, Monoclonal | 3 | 2011 | 1262 | 0.080 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2009 | 81 | 0.080 |
Why?
| | Treatment Failure | 1 | 2009 | 331 | 0.080 |
Why?
| | Fluorouracil | 1 | 2009 | 152 | 0.080 |
Why?
| | Pancreaticoduodenectomy | 1 | 2009 | 133 | 0.080 |
Why?
| | Deoxycytidine | 1 | 2009 | 138 | 0.070 |
Why?
| | Nephrectomy | 1 | 2009 | 150 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2009 | 270 | 0.070 |
Why?
| | Technology Assessment, Biomedical | 1 | 2007 | 29 | 0.070 |
Why?
| | Esophagoscopy | 1 | 2009 | 184 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 214 | 0.070 |
Why?
| | Treatment Outcome | 6 | 2010 | 9084 | 0.070 |
Why?
| | Piperazines | 1 | 2009 | 309 | 0.070 |
Why?
| | Needs Assessment | 1 | 2008 | 314 | 0.070 |
Why?
| | Aged | 8 | 2011 | 19061 | 0.070 |
Why?
| | Prognosis | 2 | 2011 | 3328 | 0.070 |
Why?
| | Pyrimidines | 1 | 2009 | 376 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 1879 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 384 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2011 | 858 | 0.060 |
Why?
| | Aged, 80 and over | 6 | 2011 | 6344 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1796 | 0.060 |
Why?
| | Patient Care Team | 1 | 2008 | 517 | 0.060 |
Why?
| | Decision Making | 1 | 2010 | 782 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2008 | 795 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 731 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2011 | 1629 | 0.050 |
Why?
| | Middle Aged | 8 | 2011 | 26719 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 2011 | 2279 | 0.040 |
Why?
| | Female | 9 | 2011 | 59461 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 6112 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2177 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 923 | 0.040 |
Why?
| | Adult | 7 | 2011 | 30528 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2011 | 4411 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 4509 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2009 | 1167 | 0.030 |
Why?
| | Animals | 3 | 2011 | 31692 | 0.030 |
Why?
| | Gene Expression | 2 | 2010 | 1421 | 0.030 |
Why?
| | Male | 7 | 2011 | 55549 | 0.030 |
Why?
| | Disease Progression | 2 | 2009 | 2380 | 0.020 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 38 | 0.020 |
Why?
| | Genes, ras | 1 | 2010 | 91 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 118 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 61 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 135 | 0.020 |
Why?
| | Oncogenes | 1 | 2010 | 103 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2010 | 126 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 192 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2009 | 63 | 0.020 |
Why?
| | Capecitabine | 1 | 2009 | 45 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 797 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 993 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 17 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
| | K562 Cells | 1 | 2008 | 73 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 115 | 0.020 |
Why?
| | Italy | 1 | 2008 | 92 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2009 | 182 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 169 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2008 | 256 | 0.020 |
Why?
| | Gastrectomy | 1 | 2009 | 82 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 157 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2008 | 125 | 0.020 |
Why?
| | Bevacizumab | 1 | 2008 | 115 | 0.020 |
Why?
| | Genome | 1 | 2010 | 271 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2009 | 332 | 0.020 |
Why?
| | Methionine | 1 | 2008 | 144 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 2009 | 121 | 0.020 |
Why?
| | Choline | 1 | 2008 | 106 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 442 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 367 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 309 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2008 | 184 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 330 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1147 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1121 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 718 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10455 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2008 | 308 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 698 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2007 | 281 | 0.020 |
Why?
| | Survival Analysis | 1 | 2009 | 1211 | 0.020 |
Why?
| | Genotype | 1 | 2010 | 1760 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 296 | 0.020 |
Why?
| | Immunotherapy | 1 | 2008 | 474 | 0.010 |
Why?
| | Mice | 2 | 2011 | 14859 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 663 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 931 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 17830 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2710 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2537 | 0.010 |
Why?
| | Rats | 1 | 2008 | 4958 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 2967 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 3531 | 0.010 |
Why?
| | Risk Factors | 1 | 2011 | 8628 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2011 | 12542 | 0.010 |
Why?
|
|
Maleddu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|